Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ME-401 + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ME-401||ME401|PWT-143|PWT143||PIK3CD inhibitor 25||ME-401 is a selective Pi3kd inhibitor that inhibits PI3K/AKT pathway signaling to decrease cell proliferation and induce cell death (PMID: 31506873).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 10||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02914938||Phase I||ME-401 ME-401 + Rituximab||A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma||Recruiting|